SHEN26 placebo

DRUG3 trials

Sponsors

Shenzhen Kexing Pharmaceutical Co., Ltd.

Conditions

COVID-19Healthy Participants

Phase 1

A Phase I Study of SHEN26 Capsule in Healthy Participants

CompletedNCT05504746

Shenzhen Kexing Pharmaceutical Co., Ltd.Healthy Participants

Start: 2022-08-08End: 2022-12-11Updated: 2022-12-16

Phase 2

Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19

CompletedNCT05676073

Shenzhen Kexing Pharmaceutical Co., Ltd.COVID-19

Start: 2022-12-08End: 2023-01-27Updated: 2023-06-18

Phase 3

Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19

Shenzhen Kexing Pharmaceutical Co., Ltd.COVID-19

Start: 2023-05-13End: 2024-07-31Target: 1200Updated: 2023-06-22

Related Papers

Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: a narrative literature review.

2025-01-011 citations

Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects

Expert Opinion on Investigational Drugs2024-04-252 citations